Polypeptide With Localisation/Targeting Motif TRIZ Cases
- Anti-B7-H4 Antibodies with Mutant Binding Motifs
Phage display selects high-affinity antibodies against hypo-glycosylated B7-H4 mutants to reduce immune suppression.
- TIM-4 CASTL Fusion Protein for Solid Tumor Targeting
TIM-4 CASTL fusion proteins bind phosphatidylserine on heterogeneous tumor cells, activating T cells to kill antigens that escape standard CAR therapies.
- Carrier Peptide Fragment for Eukaryotic Cell Delivery
A carrier peptide fragment enables efficient introduction of foreign substances into eukaryotic cells.
- Anti-TOSO CAR T-Cells for Selective Cancer Killing
Engineered T-cells use differential binding affinity to destroy malignant cells while sparing healthy B cells.
- HLA-G Targeted CAR T-Cell Therapy for Solid Tumors
Anti-HLA-G chimeric antigen receptors selectively target solid tumors while sparing normal tissues to reduce off-target toxicity.
- Bioorthogonal Reporter Gene System for Cell Tracking
Radionuclide-labeled ligands penetrate tissue to detect surface-expressed lipocalin reporters, bypassing light scattering limits.
- Surface-Displayed Endoglycosidase for Recombinant Protein Deglycosylation
Surface-displayed endoglycosidase on engineered eukaryotic cells deglycosylates secreted proteins, eliminating enzyme contamination and purification steps.
- Anti-LINGO-1 Antibodies Block Inhibitory Myelin Signals
Anti-LINGO-1 antibodies block inhibitory myelin proteins to overcome axon regeneration barriers in demyelinating disorders.
- Plant-Derived Transcription Activation Domains for Gene Expression
Plant-derived transcription activation domains replace viral components to provide robust gene expression without regulatory barriers.
- Epigenetic Modification Analysis via DNA Combing and Barcoding
Segmented surface stretching and affinity labeling resolve measurement precision versus throughput contradictions for comprehensive epigenome sequencing.
- DAGRS Peptides Target Oncogenes With Reduced Toxicity
Humanized DAGRS peptides inhibit oncogenes via specific membrane translocation, resolving toxicity challenges in cancer treatments.
- CAAR Cells Targeting ADAMTS13 Autoantibodies for TTP
CAAR cells eliminate pathogenic B cells to resolve TTP relapse risks.
- DENV4 Antibodies Targeting Hexameric NS1 Epitopes
DENV4-specific antibodies target stable multimeric NS1 complexes to resolve cross-reactivity and low sensitivity in secondary infection diagnosis.
- Tat-9R Fused Reprogramming Proteins for Cell Permeability
Tat-9R fused reprogramming factors improve delivery efficiency by escaping macropinosomes, avoiding viral integration risks.
- p18 Regulation in mTORC1 Signaling for Neurological Disorders
Inhibitory RNA reduces p18 levels to correct abnormal mTORC1 activation and improve synaptic plasticity in Angelman syndrome models.
- Dvl PDZ Peptide Ligands for Wnt Signaling Modulation
Optimized peptide sequences enhance binding affinity to the Dvl PDZ domain, resolving low efficacy in Wnt pathway modulation.
- Anti-PD-L1 Immunocytokines Reducing IL-2 Toxicity
Anti-PD-L1 immunocytokines fuse cytokines to antibodies, reducing toxicity from excessive IL-2R binding while enhancing anti-tumor immunity.
- Bispecific Immunotoxin Targeting EGFR and EGFRvIII
Recombinant bispecific immunotoxin binds wild-type EGFR and mutant EGFRvIII receptors to deliver cytotoxic payloads directly to tumor cells.
- Anti-BCMA CAR T Cell Dosing for Multiple Myeloma
Anti-BCMA CAR T cell compositions utilize specific dose ranges and formulation parameters to treat relapsed or refractory multiple myeloma.
- Antimicrobial Peptides Modulating Insect Microbiota for Vector Control
Antimicrobial peptides alter resident microorganism metabolism to decrease insect vector fitness, reducing disease transmission capabilities.
- Reporter Protein Fusion Antibodies Homogeneity
Transgenic animals produce homogeneous reporter fusion antibodies, eliminating chemical conjugation heterogeneity and separation steps in immunoassays.
- Inducible CAR T Cell Transduction via Lentiviral Vector
Lentiviral vector particles deliver genetic cargo to T cells using an inducible gene expression system, preventing malignant cell transduction.
- TREM2 CAR Tregs for Neuroinflammation
Sheddase-resistant TREM2 chimeric receptors on Tregs reduce inflammation by binding extracellular ligands without direct cell targeting.
- Gamma-Delta T Cell Donor Selection for Immunotherapy Efficacy
Donor selection based on Vδ2 index scores expands gamma-delta T cells with high cytotoxicity, resolving interindividual heterogeneity in treatment efficacy.
- Multifunctional Nanobody Protein for Tumor Targeting
Nanobody-based heterodimers reduce immunogenicity while maintaining dual antigen binding capability.
- Selective Polypeptide Binding Heparan Sulfate for Targeted Delivery
A polypeptide sequence binds selectively to heparan sulfate glycosaminoglycans on cell surfaces.
- Split Deaminase Base Editor for Controlled Editing
Segmented deaminase fragments reconstitute at target sites via dimerization, reducing off-target mutations and oncogenic risks.
- Chimeric Antigen Receptors Targeting Fibronectin for Solid Tumors
Chimeric antigen receptors bind oncofetal fibronectin domains to enhance immune cell infiltration into solid tumors.
- Pyk2-PRR2 Peptide Inhibits Cortactin SH3 Domain to Block Metastasis
A Pyk2-derived peptide binds the cortactin SH3 domain to inhibit invadopodia maturation and block cancer metastasis.
- CAR Polypeptide Targeting EBV Glycoprotein for Lytic Phase Cytotoxicity
Chimeric antigen receptor polypeptides bind Epstein-Barr virus glycoproteins to redirect T cell cytotoxic activity.
- Nanoparticle Chloroplast Targeting Peptide Delivery
Nanoparticle compositions linked to chloroplast-targeting peptides overcome limited transformation efficiency in diverse plant species.
- ND2 Peptides Inhibit Src Interaction for Neurological Treatment
ND2 peptides disrupt the ND2-Src protein interaction to modulate NMDA receptor activity, reducing stroke and pain side effects without blocking calcium flux.
- Anti-CD160-TM Antibodies for Selective NK Cell Targeting
Engineered CDRs target the CD160 transmembrane domain to amplify NK cell activation without systemic toxicity.
- Mutated CD28 CARs for T Cell Exhaustion
Mutated CD28 chimeric antigen receptors eliminate tonic signaling to prevent exhaustion while maintaining cytokine production and tumor killing.
- Anti-Eva1 Antibodies Target Cancer Stem Cells
Antibodies targeting Eva1 proteins eliminate resistant glioma stem cells via ADCC and CDC while sparing normal tissue.